Health
Entresto’s effect ‘unclear’ in advanced chronic heart failure: study – Korea Biomedical Review
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard…
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard therapy for heart failure with reduced ejection fraction (HFrEF).
However, a recent study showed that the treatment did not…
Continue Reading
-
Business21 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News7 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General22 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
General21 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts